![John Riggi](/sites/default/files/2023-10/TI_1023_riggi-900x400.jpg)
Based on recent data on omicron variant susceptibility to monoclonal antibodies, the Food and Drug Administration revised its emergency use authorizations for the combination therapies bamlanivimab and etesevimab and REGEN-COV (casirivimab and imdevimab) to exclude geographic regions where the omicron COVID-19 variant predominates.